Mylan's attempts to quiet a public anger over its $600 price tag for EpiPen weren't enough to escape a congressional inquiry.
The House Oversight and Government Reform Committee called for the generic drug maker to turn over documents on the company's revenue and manufacturing costs to better understand the price increase for the life-saving allergy treatment.
The request for documents, outlined in a letter Monday from committee leaders, comes the same day Mylan announced plans to release a cheaper version of the EpiPen, which now costs about $600 for a two-pack.
"While families and schools are struggling to keep up with your company's unreasonable price increases, Mylan has profited richly from its pricing strategy," said the letter from committee Chairman Jason Chaffetz, R-Utah, and Rep. Elijah Cummings of Maryland, the top Democrat on the panel. "Your company made EpiPen its first billion-dollar product, generating $1.19 billion in sales revenue for the company's specialty drug segment in 2014."
The company acquired the allergy drug in 2007 and since then has raised the price by 400 percent.
The committee asked for the sales of EpiPen since the acquisition and expenses for making the drug. It also called for how much Mylan spent on lobbying from 2007 to 2016.
Lawmakers also asked for any discussions with any federal officials about EpiPen coverage under the Affordable Care Act.
The committee set a deadline for the documents by Sept. 12. It also asked for a briefing by Sept. 6 from Mylan officials.
The letter comes the same day that Mylan announced a cheaper version of the generic drug that will cost $300, half the cost of the $600 version.
The move comes after an unsuccessful attempt last week to offer a $300 discount card and expand patient assistance programs. Some lawmakers balked that the discount card was nothing but a PR move.
Lawmakers are also skeptical of the latest attempt to offer a cheaper version of EpiPen.
Sen. Richard Blumenthal, D-Conn., said the announcement offered more questions than answers, "including why the price is still astronomically high, and whether its action is a pre-emptive strike against a competing generic."
Blumenthal was referring to an application from drug maker Teva for a similar EpiPen product. However, that product has yet to receive approval from the FDA, which said that Teva's application had some problems.
Teva has said that the launch of the competing EpiPen will be delayed until at least 2017, according to a March report in Bloomberg.